Altimmune (ALT) Total Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Non-Current Liabilities data on file, last reported at $45.8 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $45.8 million, up 764.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.8 million (up 764.19% YoY), and the FY2025 annual result was $49.3 million, up 824.65% from the prior year.
• Total Non-Current Liabilities eased to $45.8 million in Q1 2026 per ALT's latest filing, from $49.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $49.3 million in Q4 2025 and troughed at $4.1 million in Q1 2024.
• A 5-year average of $16.7 million and a median of $5.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 66.41% in 2022, then jumped 824.65% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $4.6 million in 2022, then dropped by 3.99% to $4.4 million in 2023, then advanced by 21.19% to $5.3 million in 2024, then jumped by 824.65% to $49.3 million in 2025, then retreated by 7.01% to $45.8 million in 2026.
• Business Quant data shows ALT's Total Non-Current Liabilities at $45.8 million in Q1 2026, $49.3 million in Q4 2025, and $27.1 million in Q3 2025.